21 publishers · first seen Mon, 02 Nov 2026 14:01 UTC · updated Tue, 03 Nov 2026 16:01 UTC
The U.S. Food and Drug Administration has approved a generic version of lenacapavir, a drug that offers nearly complete protection from HIV with just two shots a year. Developed by Gilead Sciences, lenacapavir is expected to cost $40 a year per person in 120 low- and middle-income countries, significantly less than the U.S. list price of $28,218. The generic version, developed by India-based Dr. Reddy's Laboratories, aims to increase accessibility and affordability, potentially helping to curb the global HIV epidemic. However, demand for the drug still outstrips supply, and some health organizations are calling for more action to ensure widespread availability.
In Mbarara, Uganda, sex workers like Lisa Mutoni face challenges in accessing lenacapavir, despite its potential benefits. Mutoni, who takes HIV-prevention medication, says she would benefit greatly from lenacapavir but finds it unavailable when she seeks it. Health experts believe lenacapavir has the potential to significantly impact the HIV epidemic globally due to its long-lasting effects, but current production and distribution are insufficient to meet demand.
Content auto-generated. May contain inaccuracies.